U.S. Markets open in 9 hrs 19 mins

Agile Therapeutics, Inc. (AGRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3400-0.0100 (-0.74%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3500
Open1.3600
Bid1.3400 x 1300
Ask1.3500 x 1100
Day's Range1.3400 - 1.3699
52 Week Range1.2800 - 3.8900
Volume616,360
Avg. Volume1,081,207
Market Cap118.273M
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-0.6120
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.25
  • Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference
    GlobeNewswire

    Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference

    PRINCETON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the company will be participating virtually in the William Blair 41st Annual Growth Stock Conference. Chairman and Chief Executive Officer Al Altomari is scheduled to participate in a fireside chat on Tuesday, June 1, 2021 at 10:20 a.m. Eastern Time. The fireside chat will be webcast live and can be accessed in the Events and Presentations section of the Agile Therapeutics website or by clicking here: https://wsw.com/webcast/blair58/agrx/1940510. The webcast will be archived on the Agile Therapeutics website for 30 days following the event. About Agile Therapeutics, Inc. Agile Therapeutics is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website. Contact: Matt RileyHead of Investor Relations & Corporate Communicationsmriley@agiletherapeutics.com

  • Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference
    GlobeNewswire

    Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference

    PRINCETON, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET. The fireside chat will be webcast live and can be accessed in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/, or by clicking here: https://event.on24.com/wcc/r/3173531/F391B23E756682EFEFE4952267784F45 The webcast will be archived on the Agile Therapeutics website for 30 days following the event. About Agile Therapeutics, Inc. Agile Therapeutics is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website. Contact: Matt RileyHead of Investor Relations & Corporate Communicationsmriley@agiletherapeutics.com

  • Agile Therapeutics (AGRX) Q1 2021 Earnings Call Transcript
    Motley Fool

    Agile Therapeutics (AGRX) Q1 2021 Earnings Call Transcript

    AGRX earnings call for the period ending March 31, 2021.